Delivery of antibiotics to the respiratory tract: An update

Expert Opinion on Drug Delivery

Volumn 6, Issue 9, 2009, Pages 897-905

  Traini, Daniela ^a   Young, Paul M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibiotics; Dry powder; Inhalation; Nebuliser; Pressurised metered dose

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ARIKACE; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINATE; BECLOMETASONE; CAPREOMYCIN; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; CROMOGLYCATE DISODIUM; CYCLODEXTRIN; DAPSONE; DOXYCYCLINE; FORMOTEROL; FORMOTEROL FUMARATE; GENTAMICIN; ISONIAZID; LEVOFLOXACIN; MP 376; PLACEBO; POLYGLACTIN; PULVINAL; PYRAZINAMIDE; RIFAMPICIN; SALBUTAMOL; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ASTHMA; BACTERIAL INFECTION; BRONCHIECTASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG TISSUE LEVEL; DRY POWDER; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; LIPOSOMAL DELIVERY; LUNG FIBROSIS; LUNG INFECTION; LUNG TUBERCULOSIS; METERED DOSE INHALER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; NEBULIZER; NONHUMAN; PNEUMONIA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; RESPIRATORY TRACT INFECTIONS;

EID: 70249104706     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903110710     Document Type: Review

References (93)

1. WHO. The world health report 2003-shaping the future. Available from: http://www.who.int/whr/2003/en/
2. Touw DJ, de Boer AH, Lerk CF, et al. Comparative evaluation of preliminary in vitro deposition results for tobramycin from WISTO Senior nebulizer and two different dry powder inhalers, in: D.J. Touw (Ed.), Optimization of Tobramycin Treatment in Cystic Fibrosis, Leiden, Thesis University of Leiden, 1996. pp. 179-188
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19(1):3-36 • An important review on the fundamentals of macromolecule absorption by the lungs.
4. Kim CS, Follinsbee LJ. Physiological and biomechanical factors relevant to inhaled drug delivery. In: Dekker M, editor, Inhalation delivery of therapeutic peptides and proteins. New York: Adjei, A.W. Gupta, P.K. 1997. p. 3-25
5. Groneberg DA, Witt C, Wagner U, et al. Fundamentals of pulmunary delivery. Respir Med 2003;97:382-387
6. Kuhn RJ. Formulation of aerosolized therapeutics. Cardiopulm Crit Care 2001;120:94-98
7. Smith AL. What drug? What dose? What regimen? What formulation? J Cyst Fibros 2002;1(Suppl 2):189-193 • A basic read for the understanding of antibiotics delivery to the lungs.
8. Preston WC, Saiman L. Use of aerosolised antibiotics in patients with cystic fibrosis. Chest 1999;116:775-788 (Pubitemid 29428499)
9. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):600-612 (Pubitemid 37491711)
10. de Boer AH, Hagedoorn P, Westerman EM, et al. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur J Pharm Biopharm 2006;28:171-178 (Pubitemid 43786268)
11. Young PM, Thompson J, Woodcock D, et al. The development of a novel high-dose pressurized aerosol dry-powder device (padd) for the delivery of pumactant for inhalation therapy. Aerosol Med 2004;17:123-128 (Pubitemid 38955672)
12. Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. New Engl J Med 2006;354(2):141-150
13. Dally M, Kurrle S, Breslin A. Ventilatory effects of aerosol gentamicin. Thorax 1978;33:54-56
14. Beasley R, Hendeles L. Preservatives in nebulizer solutions: risks without benefit-a further comment. Pharmacotherapy 1999;19:473-474 (Pubitemid 29160165)
15. Beasley R, Burgess C, Holt S. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J Allergy Clin Immunol 2001;107:222-223 (Pubitemid 32173895)
16. Asmus MJ, Sherman J, Hendeles L. Bronchoconstrictor additives inbronchodilator solutions. J Allergy Clin Immunol 1999;104:553-560
17. Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic-fibrosis. Pediatr Pulm 1989;6(2):91-98
18. Ramsey B, Burns J, Smith AL. Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis. The results of two phase III placebo controlled clinical trials. Pediatr Pulmonol 1997;24(Suppl 14):137-138
19. Ramsey B, Pepe MS, Quan JM. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30 •• Pivotal paper on the TOBI development.
20. Le Brun PPH, de Boer AH, Gjaltema D, et al. Inhalation of tobramycin in cystic fibrosis-Part 1: The choice of a nebulizer. Int J Pharm 1999;189(2):205-214 (Pubitemid 29481756)
21. Le Brun PPH, de Boer AH, Gjaltema D, et al. Inhalation of tobramycin in cystic fibrosis-Part 2. Optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. Int J Pharm 1999;189(2):215-225 (Pubitemid 29481757)
22. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-226 (Pubitemid 34754166)
23. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20(3):658-664
24. Geller DE, Rosenfeld M, Waltz DA, et al. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003;123(1):28-36 (Pubitemid 36126710)
25. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127(4):1420-1426 (Pubitemid 46224309)
26. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21(1):71-76 •• A comprehensive and up-to-date paper on aerosol antibiotics in non-CF bronchiestasis.
27. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54(5):658-669 •• A comprehensive and up-to-date paper on aerosol antibiotics in CF.
28. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care 2009;54(6):754-768 •• One of the few recent papers dealing with delivery devices for CF.
29. Berlana D, Llop J, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62(1):39-47 (Pubitemid 40394633)
30. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of pseudomonas-aeruginosa infection in patients with cystic-fibrosis. Lancet 1981;2(8256):1137-1139
31. Kun P, Landau LI, Phelan PD. Nebulised gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984;20:43-45 (Pubitemid 14123235)
32. Valle MJD, Lopez FG, Hurle ADG, Navarro AS. Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung. Antimicrob Agents Chemother 2007;51(10):3771-3774 (Pubitemid 47519377)
33. Waldman RH, Pearce DE, Martin RA. Pentamidine Isothionate levels in lungs, livers, and kidneys of rats after aerosol or intramuscular administration. Am Rev Respir Dis 1973;108(4):1004-1006
34. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic-fibrosis. Am Rev Respir Dis 1987;136(6):1445-1449
35. Carbone E, Nacinovich F, Stamboulian D. New therapeutic strategies with teicoplanin. Medicina-Buenos Aire 2002;62:25-29
36. Carswell F, Ward C, Cook DA, Speller DCE. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic-fibrosis. Br J Dis Chest 1987;81(4):356-360 (Pubitemid 17164863)
37. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic-fibrosis infected with pseudomonas-aeruginosa. Br J Dis Chest 1987;81(3):272-279
38. Maclusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic-fibrosis colonized with pseudomonas- aeruginosa. Pediatr Pulm 1989;7(1):42-48
39. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic-fibrosis. N Engl J Med 1993;328(24):1740-1746 (Pubitemid 23170123)
40. Stephens D, Garey N, Isles A, et al. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic-fibrosis. Pediatr Infect Dis J 1983;2(3):209-211
41. Schaad UB, Wedgwoodkrucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic-fibrosis. J Pediatr 1987;111(4):599-605 (Pubitemid 17140544)
42. Nolan G, Mcivor P, Levison H, et al. Antibiotic-Prophylaxis in cystic-fibrosi-inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr 1982;101(4):626-630
43. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulized colomycin for early pseudomonas colonization in cystic-fibrosis. Lancet 1985;1(8433):865
44. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation-therapy in cystic-fibrosis patients with chronic pseudomonas-aeruginosa lung infection. J Antimicrob Chemother 1987;19(6):831-838 (Pubitemid 17092071)
45. Valerius NH, Koch C, Hoiby N. Prevention of chronic pseudomonas- aeruginosa colonization in cystic-fibrosis by early treatment. Lancet 1991;338(8769):725-726
46. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulm 1997;23(5):330-335 (Pubitemid 27225208)
47. Vazquez C, Municio M, Corera M, et al. Early treatment of Pseudomonas-Aeruginosa colonization in cystic-fibrosis. Acta Paediatr 1993;82(3):308-309 (Pubitemid 23107556)
48. Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155(6):2024-2029
49. Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26(1):31-39
50. Kahata K, Hashino S, Imamura M, et al. Inhaled vancomycin-induced allergic reaction in decontamination of respiratory tracts for allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20(11):1001-1003 (Pubitemid 27510967)
51. Feeley TW, Moulin GCD, Hedleywhyte J, et al. Aerosol Polymyxin and pneumonia in seriously ill patients. New Engl J Med 1975;293(10):471-475
52. Touw DJ, Brimicombe RW, Hodson ME, et al. Inhalation of antibiotics in cystic-fibrosis. Eur Respir J 1995;8(9):1594-1604
53. Mukhopadhyay S, Singh M, Cater JI, et al. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51(4):364-368 (Pubitemid 26140199)
54. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85(4):227-234 (Pubitemid 40805619)
55. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26(4):298-303 (Pubitemid 41338657)
56. Hickey AJ, Lu DM, Ashley ED, Stout J. Inhaled azithromycin therapy. J Aerosol Med Deposition Clearance Eff Lung 2006;19(1):54-60
57. Tewes F, Brillault J, Couet W, Olivier JC. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J Control Release 2008;129(2):93-99
58. Mccoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178(9):921-928
59. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulm 2008;43(1):47-58
60. European medicines agency pre-authorisation evaluation of medicines for human use. London; 2005
61. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulm 2006;41(7):656-665
62. Gilead. Aztreonam for inhalation solution. 2009. Available from: http://www.gilead.com/pipeline
63. Geller D. Aerosol antibiotics in cystic fibrosis. Respir Care Cyst Fibros 2009;54(5):658-670 •• An important publication that summarises recent developments in this area.
64. Aradigm. Liposomal Ciprofloxacin. 2009. Available from: http://www.aradigm.com/products-pipeline.html
65. Transave. Arikace™-a potential new weapon in the treatment of gram-negative lung infections. 2009. Available from: http://www.transaveinc.com/ products.shtml#amik
66. Nektar. Anti-Infectives. 2009. Available from: http://www.nektar.com/ product-pipeline/all-phases.html
67. Mpex Pharmaceuticals I. Produc development programs. 2009. Available from: http://www.mpexpharma.com/mp-376.html
68. Smyth HDC. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2005;2(1):53-74 (Pubitemid 40123883)
69. Conway SP. Evidence for using nebulised antibiotics in cystic fibrosis. Arch Dis Child 1999;80(4):307-309 • An interesting overview that summarises evidence for the rationale of using nebulised antibiotics in cystic fibrosis.
70. Goldman JM, Bayston SM, Oconnor S, Meigh RE. Inhaled micronized gentamicin powder-a new delivery system. Thorax 1990;45(12):939-940
71. Crowther Labiris RN, Holbrook AM, Crystyn H, et al. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. Am J Respir Crit Care Med 1999;160:1711-1716
72. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18(10):1405-1410 (Pubitemid 32977245)
73. de Boer AH, Le Brun PPH, van der Woude HG, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 2002;54(1):17-24
74. Le Brun PPH, de Boer AH, Mannes GPM, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2 Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002;54(1):25-32 (Pubitemid 34663853)
75. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124(1):360-366
76. Geller DE, Konstan MW, Konstan MW, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulm 2007;42(4):307-313
77. Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 2006;23(5):931-940 (Pubitemid 43781401)
78. Pilcer G, Goole J, Van Gansbeke B, et al. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur J Pharm Biopharm 2008;68(2):413-421
79. Parlati C, Buttini F, Ammit AJ, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res 2009;26(5):1084-1092
80. Labiris NRC, Holbrook AM, Chrystyn H, et al. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis-A pilot study. Am J Respir Crit Care Med 1999;160(5):1711-1716
81. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007;51(8):2830-2836 (Pubitemid 47206218)
82. Adi H, Young PM, Chan HK, et al. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 2008;97(8):3356-3366
83. Tsifansky MD, Yeo Y, Evgenov OV, et al. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 2008;10(2):254-260
84. Zhao H, Liu H, Hu T, et al. Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI). Powder Technol 2009;194(1-2):81-86
85. Arnold MM, Gonnan EM, Schieber LJ, et al. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 2007;121(1-2):100-109
86. Zithromax package insert. Available from: http://www.fda.gov/cder/foi/ label/2000/50662S29lbl.pdf-
87. Prescott WA, Johnson CE. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 2005;25(4):555-573
88. Zhao M, Yao Y, Ren Y, et al. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol 2008;187(3):214-221
89. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS Pharmscitech 2008;9(1):47-53
90. Duddu SP, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm Res 2002;19(5):689-695 (Pubitemid 34553679)
91. Barnes K. First dry powder inhalation antibiotic for cystic fibrosis. 2006. Available from: http://www.in-pharmatechnologist.com/Materials- Formulation/First-dry-powder-inhalation-antibiotic-for-cystic-fibrosis
92. Wood GC, Boucher BA, Croce MA, et al. Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 2002;22(8):972-982
93. Rouby JJ, Poete P, Delassale EM, et al. Prevention of gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients-Histologic and Bacteriological Study. Intensive Care Med 1994;20(3):187-192 (Pubitemid 24088581)